Imatinib mesylate induces massive and nonspecific aminoaciduria in CML patients

被引：3
作者：
Ianotto, Jean-Christophe [1 ]
Tempescul, Adrian [1 ]
Amet, Yolande [2 ]
Grall, Pauline [1 ]
Dalbies, Florence [1 ]
Eveillard, Jean-Richard [1 ]
Guillerm, Gaelle [1 ]
Berthou, Christian [1 ]
机构：
[1] CHRU Brest, Hop Morvan, Serv Hematol, Inst Cancerohematol, F-29609 Brest, France
[2] CHRU Brest, Hop Cavale Blanche, Biochim Lab, F-29609 Brest, France
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2012年 / 87卷 / 04期
关键词：
CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; HYPOPHOSPHATEMIA; BONE; METABOLISM; PHASE;
D O I：
10.1002/ajh.23113
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：437 / 439
页数：3
相关论文
共 15 条
[1]   Altered bone and mineral metabolism in patients receiving imatinib mesylate [J].
Berman, E ;
Nicolaides, M ;
Maki, RG ;
Fleisher, M ;
Chanel, S ;
Scheu, K ;
Wilson, BA ;
Heller, G ;
Sauter, NP .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (19) :2006-2013
[2]   SEVERE HYPOPHOSPHATEMIA DURING STEM-CELL HARVESTING IN CHRONIC MYELOID-LEUKEMIA [J].
CLARK, RE ;
LEE, ES .
BRITISH JOURNAL OF HAEMATOLOGY, 1995, 90 (02) :450-452
[3]   Partial Fanconi syndrome induced by imatinib therapy: A novel cause of urinary phosphate loss [J].
Francois, Helene ;
Coppo, Paul ;
Hayman, Jean-Philippe ;
Fouqueray, Bruno ;
Mougenot, Beatrice ;
Ronco, Pierre .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2008, 51 (02) :298-301
[4]   Renal failure associated with tyrosine kinase inhibitors-Case report and review of the literature [J].
Gafter-Gvili, Anat ;
Ram, Ron ;
Gafter, Uzi ;
Shpilberg, Ofer ;
Raanani, Pia .
LEUKEMIA RESEARCH, 2010, 34 (01) :123-127
[5]   Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: A study by the National Cancer Institute Organ Dysfunction Working Group [J].
Gibbons, Joseph ;
Egorin, Merrill J. ;
Ramanathan, Ramesh K. ;
Fu, Pingfu ;
Mulkerin, Daniel L. ;
Shibata, Stephen ;
Takimoto, Chris H. M. ;
Mani, Sridhar ;
LoRusso, Patricia A. ;
Grem, Jean L. ;
Pavlick, Anna ;
Lenz, Heinz-Josef ;
Flick, Susan M. ;
Reynolds, Sherrie ;
Lagattuta, Theodore F. ;
Parise, Robert A. ;
Wang, Yanfeng ;
Murgo, Anthony J. ;
Ivy, S. Percy ;
Remick, Scot C. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) :570-576
[6]   Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia [J].
Jonsson, Sofia ;
Olsson, Bob ;
Ohlsson, Claes ;
Lorentzon, Mattias ;
Mellstrom, Dan ;
Wadenvik, Hans .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 (07) :1101-1103
[7]   Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia [J].
Legros, L ;
Bourcier, C ;
Jacquel, A ;
Mahon, FX ;
Cassuto, JP ;
Auberger, P ;
Pagès, G .
BLOOD, 2004, 104 (02) :495-501
[8]   Role of PDGF B-chain and PDGF receptors in rat tubular regeneration after acute injury [J].
Nakagawa, T ;
Sasahara, M ;
Haneda, M ;
Kataoka, H ;
Nakagawa, H ;
Yagi, M ;
Kikkawa, R ;
Hazama, F .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (05) :1689-1699
[9]   The skeletal effects of the tyrosine kinase inhibitor nilotinib [J].
O'Sullivan, Susannah ;
Lin, Jian-Ming ;
Watson, Maureen ;
Callon, Karen ;
Tong, Pak Cheung ;
Naot, Dorit ;
Horne, Anne ;
Aati, Opetaia ;
Porteous, Fran ;
Gamble, Greg ;
Cornish, Jillian ;
Browett, Peter ;
Grey, Andrew .
BONE, 2011, 49 (02) :281-289
[10]   Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response [J].
Osorio, S. ;
Noblejas, A. Garcia ;
Duran, A. ;
Steegmann, J. L. .
AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (05) :394-395
12